



Contra Costa Health Plan
P&T Formulary Update
March 29, 2022

Changes effective: 05/10/2022

Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions

On March 25, 2022 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:

Therapeutic Class Reviews	
• Specialty Biologic Agents • Atopic dermatitis • First generation antihistamines • Skeletal Muscle Relaxants	• Oral Iron preparations • Heart Failure medications • ICS/LABA combinations
Drug Monographs	
• None	
Prior Authorization Criteria Updates	
<u>New criteria was created for the following agents:</u> • Vemlidy <u>Updates were made to the criteria for the following agents:</u> • Cialis 5mg • Suvorexant (Belsomra) <u>Criteria reviewed and unchanged:</u> • Non-opioid antitussives • Direct oral Anticoagulants <u>CCHP formulary changes were made to the following drugs:</u> • Kineret 100mg. syringe • Remicade 100mg vial • Hydroxyzine 25mg/ml IM • Hydroxyzine. 50mg/ml IM • Promethazine 25mg/ml inj • Methacarbamol 100mg/ml injection • Carisoprodol 200mg-aspirin325mg-codeine 16mg tablet • Lioresal 50mcg, 500mcg, 2,000mcg IT solution • Vitafol tablet • Fluticasone-salmeterol 55mcg, 113mcg, 232mcg powder (Airduo)	

• Pradaxa 75mg, 110mg, 150mg capsule • Pataday 0.7% drops • Opatadine 0.2% drop • Brilinta 60mg tablet • Synjardy. XR tablets • Xigduo XR tablets	
Guest Speaker(s)	
• None	
<u>CCHP P&T Committee approved the following modifications to the formulary (commercial and BHC members):</u>	
Medication Name & Dosage Strength	Approved Formulary Changes
Kineret 100mg. syringe	Removed from formulary, prior authorization required
Remicade 100mg vial	Removed from formulary, prior authorization required
Hydroxyzine 25mg/ml IM	Removed from formulary, prior authorization required
Hydroxyzine. 50mg/ml IM	Removed from formulary, prior authorization required
Promethazine 25mg/ml inj	Removed from formulary, prior authorization required
Methacarbamol 100mg/ml injection	Removed from formulary
Carisoprodol 200mg-aspirin 325mg-codeine 16mg tablet	Removed from formulary
Lioresal 50mcg, 500mcg, 2,000mcg IT solution	Removed from formulary
Vitafol tablet	Removed from formulary
Fluticasone-salmeterol 55mcg, 113mcg, 232mcg powder (Airduo)	Added to formulary, no restrictions
Pradaxa 75mg, 110mg, 150mg capsule	Added to formulary, no restrictions
Pataday 0.7% drops; Opatadine 0.2% drop	Removed prior authorization requirement and step therapy
Brilinta 60mg tablet	Removed prior authorization requirement
Synjardy. XR tablets	Added to formulary, step therapy required
Xigduo XR tablets	Added to formulary, step therapy required
New Product Reviews (including new indications)	
• Scemblix (asciminib) • Kerastat (keratin 5%) topical gel • Voxzogo (vosoritide) subQ • Ryplazim (plasminogen-tvmh) • Livtencity (maribavir) 200mg tab • Apretude (cabotegravir) IM • Oxybryta (voxelotor) tablet • Vyvgart (efgartigimod alfa-fcab) IV • Dartisla (glycopyrrolate) tablet	• Tezspire (Tezepelumab-ekko) SubQ • Recorley (levoketoconazole) tablet • Collanex (collagen) topical • Rinvoq (upadacitinib) 30mg tablet • Kimmtrak (tebentafusp-tebn) IV • Vabysmo (faricimab-syoa) IV • Cibingo (abrocitinib) tablet • Enjaymo (sutimlimab-jome) IV • Spikevax (COVID-19) Vaccine